
Faculty, Staff and Student Publications
Publication Date
10-31-2023
Journal
mBio
Abstract
Concerns over resistance and safety have been identified in the current treatment regimen for complicated urinary tract infections. Fosfomycin is a drug that is routinely used for the treatment of uncomplicated cystitis. This study shows that fosfomycin could be an oral alternative as step-down therapy for the treatment of complicated urinary tract infections, with a clinical cure rate comparable to levofloxacin but a lower microbiological success rate 3 weeks from start of antibiotics.
Keywords
Humans, Fosfomycin, Levofloxacin, Urinary Tract Infections, Anti-Bacterial Agents, Cystitis, complicated UTI, fosfomycin, oral antibiotic
DOI
10.1128/mbio.01677-23
PMID
37698412
PMCID
PMC10783529
PubMedCentral® Posted Date
September 2023
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Included in
Bioinformatics Commons, Biomedical Informatics Commons, Medical Sciences Commons, Oncology Commons